<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02326584</url>
  </required_header>
  <id_info>
    <org_study_id>SGN33A-002</org_study_id>
    <nct_id>NCT02326584</nct_id>
  </id_info>
  <brief_title>A Safety Study of SGN-CD33A in Combination With Standard-of-care in Patients With AML</brief_title>
  <official_title>A Phase 1b Dose-escalation Study of SGN-CD33A in Combination With Standard-of-care for Patients With Newly Diagnosed Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seattle Genetics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seattle Genetics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine the safety profile of vadastuximab talirine (SGN-CD33A) by itself
      (monotherapy) or in combination with other standard treatments. The main purpose of this
      study is to find the best dose and schedule for SGN-CD33A when given in combination with
      standard induction treatment, in combination with standard consolidation treatment, or by
      itself for maintenance treatment. This will be determined by observing the dose-limiting
      toxicities (the side effects that prevent further increases in dose) of SGN-CD33A. In
      addition, the pharmacokinetic profile and anti-leukemic activity of the study treatment will
      be assessed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be conducted in the following distinct parts:

      Part A: Induction dose escalation - 7+3 combined with SGN-CD33A (Day 1 and Day 4 dosing)

      Part B: Consolidation dose escalation - consolidation combined with SGN-CD33A; up to 4 cycles
      of consolidation therapy will be administered after SGN-CD33A (Day 1 of each cycle).

      Part C: Maintenance - SGN-CD33A Monotherapy; Up to 24 patients with and up to 24 patient
      without prior allogeneic stem cell transplant will be treated with SGN-CD33A. Both arms will
      enroll simultaneously. SGN-CD33A will be administered on Day 1 of each 6-week cycle for up to
      8 cycles.

      Part D: Induction plus consolidation - induction/consolidation combined with SGN-CD33A;
      patients who achieve a CR/CRi (with or without a second induction) will receive up to 4
      cycles of consolidation therapy administered after SGN-CD33A (Day 1 of each cycle).

      Part E: Induction dose escalation - 7+3 combined with SGN-CD33A (Day 1 dosing)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">April 10, 2018</completion_date>
  <primary_completion_date type="Actual">January 30, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Through 1 month following last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of laboratory abnormalities</measure>
    <time_frame>Through 1 month following last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of dose-limiting toxicity (DLT)</measure>
    <time_frame>Through 1 month following last dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete remission (CR) rate at the end of induction</measure>
    <time_frame>Through 1 month following last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leukemia-free survival</measure>
    <time_frame>Up to approximately 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to approximately 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood concentrations of SGN-CD33A and metabolites</measure>
    <time_frame>Up to approximately 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of antitherapeutic antibodies (ATA)</measure>
    <time_frame>Up to approximately 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of minimal residual disease (MRD) clearance</measure>
    <time_frame>Up to approximately 3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">116</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Acute Myelogenous Leukemia</condition>
  <arm_group>
    <arm_group_label>Induction with SGN-CD33A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>7+3 (Standard dose cytarabine for induction and daunorubicin) + SGN-CD33A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Consolidation with SGN-CD33A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose cytarabine for consolidation + SGN-CD33A (28-day cycles)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SGN-CD33A Maintenance</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SGN-CD33A Monotherapy (42-day cycles)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Induction and Consolidation with SGN-CD33A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>7+3 (standard dose cytarabine for induction and daunorubicin) + SGN-CD33A and High dose cytarabine for consolidation + SGN-CD33A</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard dose cytarabine for induction</intervention_name>
    <description>100 mg/m2/day Days 1-7</description>
    <arm_group_label>Induction with SGN-CD33A</arm_group_label>
    <arm_group_label>Induction and Consolidation with SGN-CD33A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SGN-CD33A</intervention_name>
    <description>Given intravenously Day 1 or Days 1 and 4 of each cycle</description>
    <arm_group_label>Induction with SGN-CD33A</arm_group_label>
    <arm_group_label>Induction and Consolidation with SGN-CD33A</arm_group_label>
    <arm_group_label>Consolidation with SGN-CD33A</arm_group_label>
    <arm_group_label>SGN-CD33A Maintenance</arm_group_label>
    <other_name>vadastuximab talirine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daunorubicin</intervention_name>
    <description>60 mg/m2/day Days 1-3</description>
    <arm_group_label>Induction with SGN-CD33A</arm_group_label>
    <arm_group_label>Induction and Consolidation with SGN-CD33A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High dose cytarabine for consolidation</intervention_name>
    <description>3g/m2 on Days 1, 3, and 5 of each cycle</description>
    <arm_group_label>Induction and Consolidation with SGN-CD33A</arm_group_label>
    <arm_group_label>Consolidation with SGN-CD33A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All subtypes of Acute Myeloid leukemia (except for acute promyelocytic leukemia)

          -  Eastern Cooperative Oncology Group status of 0 or 1

          -  Adequate baseline renal and hepatic function

          -  Central venous access

          -  Part specific requirements: eligible to receive induction; achieved CR/CRi with
             standard induction and eligible to receive consolidation; in CR with documented blood
             count recovery for maintenance

        Exclusion Criteria:

          -  Previous treatment for MDS or MPN for dose escalation cohorts

          -  Inadequate lung function

          -  Inadequate heart function
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Feldman, MD</last_name>
    <role>Study Director</role>
    <affiliation>Seattle Genetics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010-3000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorado Blood Cancer Institute</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardinal Bernardin Cancer Center / Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute / Wayne State University</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic, The</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James Cancer Hospital / Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>30384</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charles A. Sammons Cancer Center / Baylor University Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center / University of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2014</study_first_submitted>
  <study_first_submitted_qc>December 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 29, 2014</study_first_posted>
  <last_update_submitted>May 8, 2018</last_update_submitted>
  <last_update_submitted_qc>May 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Myeloid Leukemia</keyword>
  <keyword>Antibody-Drug Conjugate</keyword>
  <keyword>CD33 Antigen</keyword>
  <keyword>Drug Therapy</keyword>
  <keyword>Acute Myelogenous Leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

